Team:UGent/Project
From 2013.igem.org
Line 86: | Line 86: | ||
<tr> | <tr> | ||
<td> | <td> | ||
- | </html> | + | <p></html> |
- | [[File:UGent_2013_TA_TypeII.png|thumb| | + | [[File:UGent_2013_TA_TypeII.png|thumb|320px|center|<b>Mechanism of type II TA systems.</b> The antitoxin protein inhibits the toxin protein by forming a sstable complex with the toxin. This complex (as well as the antitoxin itself) is part of a feedback inhibition of the promoter.]] |
- | <html> | + | <html></p> |
</td> | </td> | ||
<td> | <td> | ||
Line 101: | Line 101: | ||
<h3>Type II</h3> | <h3>Type II</h3> | ||
<p><i>(Figure)</i><br>Antitoxins in type II TA systems are proteins and inhibit the corresponding toxin by forming a stable TA protein complex. These systems are encoded by an operon that contains the two genes encoding the toxin and antitoxin. The antitoxin has to be continuously produced, as it is less stable than the toxin. Because of this feature, the cell has a feedback mechanism to prevent growth arrest. The TA complex functions as a repressor that binds the promoter and thereby inhibits transcription. Thus, when the antitoxin is degraded and the concentration of the TA complex decreases, the TA operon is derepressed and produces more toxin and antitoxin. Finally, the concentration of the antitoxin is reestablished. The rank of the two genes differs, which can contribute to different toxin-antitoxin ratios.</p> | <p><i>(Figure)</i><br>Antitoxins in type II TA systems are proteins and inhibit the corresponding toxin by forming a stable TA protein complex. These systems are encoded by an operon that contains the two genes encoding the toxin and antitoxin. The antitoxin has to be continuously produced, as it is less stable than the toxin. Because of this feature, the cell has a feedback mechanism to prevent growth arrest. The TA complex functions as a repressor that binds the promoter and thereby inhibits transcription. Thus, when the antitoxin is degraded and the concentration of the TA complex decreases, the TA operon is derepressed and produces more toxin and antitoxin. Finally, the concentration of the antitoxin is reestablished. The rank of the two genes differs, which can contribute to different toxin-antitoxin ratios.</p> | ||
+ | <p>The toxin and antitoxin are dependent, as they are both necessary for survival. Without the antidote the cell dies, but an efficient toxin might be vital to maintain a functional antitoxin.</p> | ||
<h3>Type III</h3> | <h3>Type III</h3> | ||
Line 115: | Line 116: | ||
<h3> CcdA/CcdB </h3> | <h3> CcdA/CcdB </h3> | ||
- | <p>This type II TA system is the first identified and best studied of all TA systems, which is why we have chosen to use it in our model. The target of the CcdB protein is the A subunit of DNA gyrase. This gyrase is an essential type II topoisomerase, occurring in all bacteria but not in eukaryotes. Bacterial gyrases have the property to introduce negative supercoils into DNA, which makes them unique among topoisomerases. | + | <p>The F plasmid <i>ccd</i> (control of cell death or coupled cell division) TA module encodes the toxin CcdB and its antidote CcdA. This type II TA system is the first identified and best studied of all TA systems, which is why we have chosen to use it in our model. The <b>target</b> of the CcdB protein is the A subunit of <b>DNA gyrase</b>. This gyrase is an <b>essential</b> type II topoisomerase, occurring <b>in all bacteria but not in eukaryotes</b>. Bacterial gyrases have the property to introduce negative supercoils into DNA, which makes them unique among topoisomerases. As they are not present in eukaryotes, the toxin does not pose any risk for humans.</p> |
- | + | </html> | |
- | In the absence of its antidote CcdA, CcdB causes reduced DNA synthesis, activation of the SOS pathway, cell filamentation and eventually cell death. When CcdB interacts with a gyrase:DNA complex, it stabilises the cleavable complex. In this mode of action, CcdB acts as a poison, promoting DNA breakage mediated by gyrase. The antidote CcdA can inhibit CcdB by the formation of a tight non-covalent complex. This prevents CcdB from making a covalent complex with gyrase. But even after CcdB has formed a complex with gyrase, CcdA can still reverse the blocking CcdB caused.</p> | + | {{:Team:UGent/Templates/ToggleBoxStart}} Read more about the <i>ccd</i> module and our use of it {{:Team:UGent/Templates/ToggleBoxStart1}}{{:Team:UGent/Templates/ToggleBoxStart2}} |
+ | <html> | ||
+ | <table> | ||
+ | <tr> | ||
+ | <td> | ||
+ | <p>In the absence of its antidote CcdA, CcdB causes reduced DNA synthesis, activation of the SOS pathway, cell filamentation and eventually cell death. When CcdB interacts with a gyrase:DNA complex, it stabilises the cleavable complex. In this mode of action, CcdB acts as a poison, promoting DNA breakage mediated by gyrase. The antidote CcdA can inhibit CcdB by the formation of a tight non-covalent complex. This prevents CcdB from making a covalent complex with gyrase. But even after CcdB has formed a complex with gyrase, CcdA can still reverse the blocking CcdB caused.</p> | ||
+ | <p>As CcdA has no toxic effects in the absence of CcdB, the ccdA gene will be used as selectable marker integrated in the CIChE construct, under the control of a constitutive promoter. By adding a plasmid bearing the ccdB gene under the control of a chemically inducible promoter, we suggest it is possible to regulate the amount of CcdB present in the cell titrating the chemical inducer. If this CIChE system works, cells with a higher gene copy number could be attained by titrating higher concentrations of the chemical inducer, as these have more CcdA to compensate for the toxic CcdB.</p> | ||
+ | </td> | ||
+ | <td> | ||
+ | </html> | ||
+ | [[File:UGent_2013_TA_TypeII.png|thumb|320px|center|<b>Mechanism of type II TA systems.</b> The antitoxin protein inhibits the toxin protein by forming a sstable complex with the toxin. This complex (as well as the antitoxin itself) is part of a feedback inhibition of the promoter.]] | ||
+ | <html> | ||
+ | </td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | </table> | ||
+ | </html> | ||
+ | {{:Team:UGent/Templates/ToggleBoxEnd}} | ||
+ | <html> | ||
<h2>Construct</h2> | <h2>Construct</h2> |
Revision as of 14:59, 14 September 2013
You can read our entire literature study about our new model for stabilised gene duplication here. Below you can read the most important aspects of it. Introduction: high gene expression in industrial biotechnologyThe main goal of industrial biotechnology is to increase the yield of biochemical products using microorganisms as production hosts. This includes engineering large synthetic pathways and improving their expression. Overexpression of genes has mainly been achieved by using high or medium copy plasmids. However, studies have demonstrated that plasmid-bearing cells lose their productivity fairly quickly as a result of genetic instability.
In industrial biotechnology, a common technique to express new synthetic products and pathways is the use of plasmids as vectors. Plasmids are easy to insert into cells and replicate independently from the genome, allowing strong gene expression. Overexpression is easily achieved by using plasmids with a medium or high copy number, different promoter systems, ribosome binding sites (RBS), etc. Thanks to plasmids, the industrial biotechnology has grown substantially over the past years. However, the use of plasmids entails some important disadvantages: plasmid maintenance imposes a metabolic burden on cells and plasmids suffer from genetic instability. Metabolic burdenWhen plasmids are present in cells and replicate, they create a metabolic burden. This is defined by Bentley et al. (1990) as “the amount of resources that are taken from the host cell metabolism for foreign DNA maintenance and replication”. As a result, metabolic load causes many alterations to the physiology and metabolism of the cell and reduces the cellular fitness. The most common change is a delayed growth. This can be caused by the fact that new pathways for energy generation are activated due to the competition between cell propagation and plasmid replication. This growth retardation leads to a lower yield of the desired product. Genetic instabilityPlasmids are genetically instable due to three processes: segregational instability, structural instability and allele segregation.
Therefore a new method was developed for the overexpression of a gene of interest in the bacterial chromosome: Chemically Inducible Chromosomal evolution (CIChE). In this technique the chromosome is evolved to contain a higher number of gene copies by adding a chemical inducer.
In 2009, Tyo et al. developed a technique for the stable, high copy expression of a gene of interest in E. coli without the use of high copy number plasmids, thus avoiding their previously stated negative characteristics. They called this plasmid-free, high gene copy expression system ‘chemically inducible chromosomal evolution’. In this method, the gene of interest is integrated in the microbial genome and then amplified to achieve multiple copies and reach the desired expression level. Genomic integration guarantees ordered inheritance, resolving the problem of allele segregation. CIChE works as follows: First a construct, containing the gene(s) of interest and the antibiotic marker chloramphenicol acetyl transferase (cat) flanked by homologous regions, is delivered to and subsequently integrated into the E. coli genome. The construct can be amplified in the genome through tandem gene duplication by recA homologous recombination. Then the strain is cultured in increasing concentrations of chloramphenicol, providing a growth advantage for cells with increased repeats of the construct and thereby selecting for bacteria with a higher gene copy number (Figure).
This process is called chromosomal evolution. When the desired gene copy number is reached recA is deleted, thereby fixing the copy number. The use of CIChE-strains poses several advantages. They require no selection markers and can be cultured without the addition of antibiotics to the medium. This is in contrast to strains containing plasmids, which still need antibiotic selection. Also, in CIChE-strains yields can be tuned by varying the antibiotic concentration during chromosomal evolution. CloseIt has been shown that approximately 40 and even up to 50 gene copies can be attained using chromosomal evolution. It has also been demonstrated that, while plasmid-bearing strains lose their productivity after 40 generations due to allele segregation, gene copy number and productivity of CIChE-strains remain stable even after 70 generations. This genetic stability is considered to be the most important asset of CIChE. The original model for CIChE, however, results in bacterial strains containing a large number of antibiotic resistance genes. To make this valuable technique more widely applicable in the industry, we developed a model for chromosomal evolution based on a toxin-antitoxin system instead of antibiotic resistance. |